Literature DB >> 7664286

Interferon system defects in human malignant melanoma.

C Linge1, D Gewert, C Rossmann, J A Bishop, J S Crowe.   

Abstract

We have examined the ability of melanoma cell lines and normal human melanocytes, which have demonstrable intact IFN genes, to secrete both IFN-alpha and IFN-beta in response to induction with virus. Normal melanocytes were found to secrete both IFN-alpha and IFN-beta after virus induction. In contrast, although all but one of the melanoma lines tested were capable of secreting IFN-beta, none were capable of IFN-alpha secretion. This phenomenon was not due to defects in either translation of IFN-alpha mRNA or secretion of IFN-alpha proteins, since transfection of melanoma lines with a constitutive IFN-alpha 2b expression vector resulted in the secretion of high levels of IFN. On further examination, this inability to express natural IFN-alpha appeared to be due to a defect in activation of the IFN-alpha promoters, since constructs containing the IFN-alpha promotor were completely unresponsive to viral infection in melanoma cells but inducible in melanocytes. These results show that there is a specific disruption of IFN-alpha gene activation rather than IFN-beta in melanoma lines and suggest that this is due to disruption of a trans-acting IFN-alpha gene transcription factor. Disruption of this factor and its consequences may be important in the development of malignant melanoma.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7664286

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  13 in total

Review 1.  Vesicular stomatitis virus as a flexible platform for oncolytic virotherapy against cancer.

Authors:  Eric Hastie; Valery Z Grdzelishvili
Journal:  J Gen Virol       Date:  2012-10-10       Impact factor: 3.891

Review 2.  Understanding and altering cell tropism of vesicular stomatitis virus.

Authors:  Eric Hastie; Marcela Cataldi; Ian Marriott; Valery Z Grdzelishvili
Journal:  Virus Res       Date:  2013-06-22       Impact factor: 3.303

3.  Vesicular stomatitis virus as an oncolytic agent against pancreatic ductal adenocarcinoma.

Authors:  Andrea M Murphy; Dahlia M Besmer; Megan Moerdyk-Schauwecker; Natascha Moestl; David A Ornelles; Pinku Mukherjee; Valery Z Grdzelishvili
Journal:  J Virol       Date:  2012-01-11       Impact factor: 5.103

4.  Attenuation of V- or C-defective measles viruses: infection control by the inflammatory and interferon responses of rhesus monkeys.

Authors:  Patricia Devaux; Gregory Hodge; Michael B McChesney; Roberto Cattaneo
Journal:  J Virol       Date:  2008-04-02       Impact factor: 5.103

5.  Resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus: role of type I interferon signaling.

Authors:  Megan Moerdyk-Schauwecker; Nirav R Shah; Andrea M Murphy; Eric Hastie; Pinku Mukherjee; Valery Z Grdzelishvili
Journal:  Virology       Date:  2012-12-14       Impact factor: 3.616

6.  Evaluation of an attenuated vesicular stomatitis virus vector expressing interferon-beta for use in malignant pleural mesothelioma: heterogeneity in interferon responsiveness defines potential efficacy.

Authors:  Vassiliki Saloura; Liang-Chuan S Wang; Zvi G Fridlender; Jing Sun; Guanjun Cheng; Veena Kapoor; Daniel H Sterman; Ronald N Harty; Atsushi Okumura; Glen N Barber; Richard G Vile; Mark J Federspiel; Stephen J Russell; Leslie Litzky; Steven M Albelda
Journal:  Hum Gene Ther       Date:  2010-01       Impact factor: 5.695

7.  Breaking resistance of pancreatic cancer cells to an attenuated vesicular stomatitis virus through a novel activity of IKK inhibitor TPCA-1.

Authors:  Marcela Cataldi; Nirav R Shah; Sébastien A Felt; Valery Z Grdzelishvili
Journal:  Virology       Date:  2015-08-29       Impact factor: 3.616

Review 8.  Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded.

Authors:  Roberto Cattaneo; Tanner Miest; Elena V Shashkova; Michael A Barry
Journal:  Nat Rev Microbiol       Date:  2008-07       Impact factor: 60.633

9.  Follow-up analysis of a randomized phase III immunotherapeutic clinical trial on melanoma.

Authors:  Robert Suriano; Shilpi Rajoria; Andrea L George; Jan Geliebter; Raj K Tiwari; Marc Wallack
Journal:  Mol Clin Oncol       Date:  2013-03-20

Review 10.  Interferons in cancer immunoediting: sculpting metastasis and immunotherapy response.

Authors:  Michelle von Locquenghien; Catalina Rozalén; Toni Celià-Terrassa
Journal:  J Clin Invest       Date:  2021-01-04       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.